A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers
Conclusion:
Biweekly cisplatin, fixed-dose-rate gemcitabine, and infusional 5-FU demonstrated a high response rate and were well tolerated, encouraging further investigation of this regimen in metastatic pancreatic and biliary cancers.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
More News: Adenocarcinoma | Anemia | Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Hematology | Pancreas | Pancreatic Cancer | Study | Thrombocytopenia | Toxicology